XML 40 R31.htm IDEA: XBRL DOCUMENT
v3.25.1

Collaboration Agreements, License Agreement and Revenues (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2024
Schedule of Drug Product Revenue | Drug product revenue from commercial-grade API or bulk drug product sales to Astellas and AstraZeneca was as follows for the years ended December 31, 2024 and 2023 (in thousands):
|  | Years Ended December 31, |
|  | 2024 |  |  | 2023 |
Astellas Japan Agreement |  | $ | (2,872 | ) |  | $ | 15,656 |
Astellas Europe Agreement |  |  | 4,874 |  |  |  | 3,097 |
AstraZeneca U.S./RoW Agreement |  |  | 25,671 |  |  |  | — |
Drug product revenue, net |  | $ | 27,673 |  |  | $ | 18,753 |
Summary of Amounts Recognized as Revenue | Amounts recognized as revenue under the agreements with Eluminex were as follows for the years ended December 31, 2024 and 2023 (in thousands):
|  |  |  | Years Ended December 31, |
Agreement |  | Performance Obligation |  | 2024 |  |  | 2023 |
Eluminex |  | License revenue |  | $ | — |  |  | $ | 7,000 |
|  | Other revenue - contract manufacturing |  | $ | 117 |  |  | $ | 966 |
|  | Other revenue - patent transfer |  | $ | — |  |  | $ | 500 |
AstraZeneca Agreements [Member] |
Roll-forward of Related Contract Liabilities | The following table includes a roll-forward of the related deferred revenue that is considered as a contract liability (in thousands):
|  | Balance at December 31, 2023 |  |  | Additions |  |  | Recognized as Revenue (Discontinued Operations) |  |  | Currency Translation and Other |  |  | Balance at December 31, 2024 |
AstraZeneca China performance obligation - deferred revenue |  | $ | (179,851 | ) |  | $ | (112,503 | ) |  | $ | 159,010 |  |  | $ | 1,247 |  |  | $ | (132,097 | )
Drug Product Revenue, Net [Member] |
Roll-forward of Related Contract Liabilities | The following table includes a roll-forward of the above-mentioned deferred revenues that are considered as contract liabilities related to drug product (in thousands):
|  | Balance at December 31, 2023 |  |  | Additions |  |  | Recognized as Revenue |  |  | Reclassified to Accrued Liability / Accounts Payable |  |  | Balance at December 31, 2024 |
Drug product revenue - deferred revenue: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Astellas Europe Agreement |  | $ | (16,925 | ) |  | $ | (4,441 | ) |  | $ | 4,295 |  |  | $ | 7,170 |  |  | $ | (9,901 | )
Europe [Member] |
Summary of License Revenue and Development Revenue Recognized under Agreement | Amounts recognized as license revenue and development revenue under the Astellas Europe Agreement were as follows for the years ended December 31, 2024 and 2023 (in thousands):
|  |  |  | Years Ended December 31, |
Agreement |  | Performance Obligation |  | 2024 |  |  | 2023 |
Astellas Europe Agreement |  | Development revenue |  | $ | 1,395 |  |  | $ | 6,452 |
U.S./RoW and China [Member] |
Summary of License Revenue and Development Revenue Recognized under Agreement | Amounts recognized as license revenue and development revenue under the AstraZeneca U.S./RoW Agreement and the AstraZeneca China Agreement were as follows for the years ended December 31, 2024 and 2023 (in thousands):
|  |  |  | Years Ended December 31, |
Agreement |  | Performance Obligation |  | 2024 |  |  | 2023 |
AstraZeneca U.S./RoW Agreement and AstraZeneca China Agreement |  | License revenue |  | $ | — |  |  | $ | 2,649 |
|  | Development revenue |  | $ | 418 |  |  | $ | 9,473 |

X
- Definition Contract with customer milestone method. + References No definition available. + Details
Name: | fgen_ContractWithCustomerMilestoneMethodTableTextBlock
Namespace Prefix: | fgen_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Schedule of drug product revenue. + References No definition available. + Details
Name: | fgen_ScheduleOfDrugProductRevenueTableTextBlock
Namespace Prefix: | fgen_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10 + Details
Name: | us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the type of arrangements and the corresponding amounts that comprise the current and noncurrent balance of deferred revenue as of the balance sheet date. + References No definition available. + Details
Name: | us-gaap_DeferredRevenueByArrangementDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=fgen_AstraZenecaAgreementsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=fgen_DrugProductRevenueMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=srt_EuropeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=fgen_UnitedStatesRestOfWorldAndChinaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |